ClinicalTrials.gg
CompletedNCT02502500Updated Nov 14, 2018

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

A Phase 1 interventional study of Celecoxib and AKB-6548 in Healthy Volunteers, sponsored by Akebia Therapeutics. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To assess the single dose pharmacokinetics (PK) of celecoxib in healthy subjects when administered alone and following multiple daily doses of AKB-6548.

Read the detailed description

To assess the single dose plasma pharmacokinetics (PK), safety, and tolerability of celecoxib in healthy subjects with CYP2C9 extensive metabolizer (EM) genotype when administered alone and following multiple daily doses of AKB-6548.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between 18 and 55 years of age, inclusive, and with a between 18 and 30 kg/sq.meters, inclusive.
  • Subjects with the following genotype based upon pharmacogenetic testing results: CYP2C9 EM: *1*1.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver disease.
  • Positive serology results for , , and at Screening.
  • Significant renal impairment as evidenced by an estimated (eGFR) of \<65 mL/minute/1.73 sq.meters.
  • Known to celecoxib or sulfonamides.
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Known active cancer or history of chemotherapy use within the previous 24 months.
  • Current or past history of gastric or duodenal ulcers or other diseases of the GI tract (including gastric bypass surgeries) that could interfere with absorption of study drug.
  • Current or past history of gastrointestinal bleeding.
  • Any history of alcohol or drug abuse within the previous year prior to Screening.
  • Subjects with a known history of smoking and/or have used nicotine or nicotine containing products within the past 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Celecoxib

    Celecoxib

    Drug: Celecoxib

  • Experimental
    AKB-6548 and Celecoxib

    AKB-6548; celecoxib

    Drug: Celecoxib · Drug: AKB-6548

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters (Cmax)

    maximum observed plasma concentration (Cmax) for celecoxib

    Time frame: pre-dose to 48 hours post-dose

  2. PK parameters (time to reach Cmax )

    time to reach Cmax for celecoxib

    Time frame: pre-dose to 48 hours post-dose

  3. PK parameters (t½)

    terminal elimination half-life (t½) for celecoxib

    Time frame: from pre-dose to 48 hours post-dose

  4. PK parameters (AUC0-t)

    concentration (AUC0-t) for celecoxib

    Time frame: pre-dose to 48 hours post-dose

  5. PK parameters (area under the plasma concentration-time curve from 0 to last quantifiable)

    area under the plasma concentration-time curve from 0 to last quantifiable

    Time frame: pre-dose to 48 hours post-dose

  6. PK parameters (AUC0-inf)

    AUC from time 0 to infinity (AUC0-inf) for celecoxib

    Time frame: from pre-dose to 48 hours post-dose

  7. PK parameters (CL/F)

    apparent oral clearance (CL/F) for celecoxib

    Time frame: pre-dose to 48 hours post-dose

  8. PK parameters (Vz/F)

    apparent volume of distribution during the terminal phase (Vz/F) for celecoxib

    Time frame: pre-dose to 48 hours post-dose

Secondary outcomes

  1. Safety and Tolerability will be measured by vital signs

    The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for vital signs, clinical laboratory assays

    Time frame: up to ten days

  2. Safety and Tolerability will be monitoring of adverse events (AEs)

    The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for adverse events (AEs)

    Time frame: up to ten days

  3. Safety and Tolerability will be measured by clinical assays

    The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for clinical laboratory assays

    Time frame: up to ten days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jul 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Jul 20, 2015
Start
Jul 2015
Primary completionActual
Jul 2015
CompletionActual
Sep 2015
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02502500
Responsible party
Sponsor
First posted
Jul 20, 2015
Start date
Jul 2015
Primary completion
Jul 2015
Completion
Sep 2015
Last update
Nov 14, 2018

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Vadadustat

Start the discussion